• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

延长药物传递系统在眼表面停留时间的策略。

Strategies to prolong the residence time of drug delivery systems on ocular surface.

机构信息

Department of Pharmacy, University of Pisa, Via Bonanno 33, 56126 Pisa, Italy.

Department of Pharmacy, University of Pisa, Via Bonanno 33, 56126 Pisa, Italy; Department of Pharmacy, University of Pisa, Via Bonanno 33, 56126 Pisa, Italy; Interdepartmental Research Center "Nutraceuticals and Food for Health", University of Pisa, Pisa 56100, Italy.

出版信息

Adv Colloid Interface Sci. 2021 Feb;288:102342. doi: 10.1016/j.cis.2020.102342. Epub 2020 Dec 13.

DOI:10.1016/j.cis.2020.102342
PMID:33444845
Abstract

Ocular diseases may be treated via different routes of administration, such as topical, intracameral, intravitreal, oral and parenteral. Among them the topical route is most accepted by patients, although it provides in many cases the lowest bioavailability. Indeed, when a topical formulation reaches the precorneal area, i.e., the drug absorption and/or action site, it is rapidly eliminated due to eye protection mechanisms such as blinking, basal and reflex tearing, and naso-lacrimal draining. To avoid this and to reduce the frequency of dosing, various strategies have been developed to prolong drug residence time after topical administration. These strategies include the use of viscosity increasing and mucoadhesive excipients as well as combinations thereof. From the drug delivery system point of view, liquid and semisolid formulations are preferred over solid formulations such as ocular inserts and contact lenses. Furthermore, liquid and semisolid formulations can contain nano- and microcarrier systems that contribute to a prolonged residence time. Within this review an overview about the different types of excipients and formulations as well as their performance in valid animal models and clinical trials is provided.

摘要

眼部疾病可以通过不同的给药途径治疗,例如局部、前房内、玻璃体内、口服和肠胃外。其中,局部途径最受患者接受,尽管在许多情况下它提供的生物利用度最低。事实上,当局部制剂到达角膜前区(即药物吸收和/或作用部位)时,由于眨眼、基础和反射性流泪以及鼻泪管引流等眼部保护机制,它会迅速被清除。为了避免这种情况并减少给药频率,已经开发了各种策略来延长局部给药后药物的停留时间。这些策略包括使用粘度增加和粘膜粘附赋形剂以及它们的组合。从药物传递系统的角度来看,液体和半固体制剂优于固体制剂,如眼内插入物和隐形眼镜。此外,液体和半固体制剂可以包含纳米和微载体系统,有助于延长停留时间。在本次综述中,概述了不同类型的赋形剂和制剂及其在有效动物模型和临床试验中的性能。

相似文献

1
Strategies to prolong the residence time of drug delivery systems on ocular surface.延长药物传递系统在眼表面停留时间的策略。
Adv Colloid Interface Sci. 2021 Feb;288:102342. doi: 10.1016/j.cis.2020.102342. Epub 2020 Dec 13.
2
Novel in situ gelling ophthalmic drug delivery system based on gellan gum and hydroxyethylcellulose: Innovative rheological characterization, in vitro and in vivo evidence of a sustained precorneal retention time.基于结冷胶和羟乙基纤维素的新型原位凝胶眼用给药系统:创新的流变学特征、体外和体内证据表明具有延长的角膜前滞留时间。
Int J Pharm. 2020 Jan 25;574:118734. doi: 10.1016/j.ijpharm.2019.118734. Epub 2019 Nov 6.
3
A review on topical ophthalmic drug delivery system: Reference to viscosity enhancer.眼用药物传递系统的综述:黏度增强剂的参考
Polim Med. 2024 Jan-Jun;54(1):71-84. doi: 10.17219/pim/166413.
4
Recent advances in ocular drug delivery.眼部药物输送的最新进展。
Drug Dev Ind Pharm. 2013 Nov;39(11):1599-617. doi: 10.3109/03639045.2012.736515. Epub 2012 Nov 16.
5
In situ gelling and mucoadhesive polymers: why do they need each other?原位凝胶和黏膜黏附聚合物:它们为什么需要彼此?
Expert Opin Drug Deliv. 2018 Oct;15(10):1007-1019. doi: 10.1080/17425247.2018.1517741. Epub 2018 Sep 7.
6
Phenylboronic acid-tethered chondroitin sulfate-based mucoadhesive nanostructured lipid carriers for the treatment of dry eye syndrome.基于硼酸修饰的硫酸软骨素的黏附性纳米结构化脂质载体治疗干眼综合征。
Acta Biomater. 2019 Nov;99:350-362. doi: 10.1016/j.actbio.2019.08.035. Epub 2019 Aug 23.
7
Topical ocular drug delivery systems: Innovations for an unmet need.眼部局部给药系统:满足未被满足需求的创新
Exp Eye Res. 2022 May;218:109006. doi: 10.1016/j.exer.2022.109006. Epub 2022 Mar 4.
8
Solid lipid nanocarriers in drug delivery: characterization and design.固体脂质纳米载体在药物传递中的应用:特性与设计。
Expert Opin Drug Deliv. 2018 Aug;15(8):771-785. doi: 10.1080/17425247.2018.1504018.
9
Recent Advances in the Development of In Situ Gelling Drug Delivery Systems for Non-Parenteral Administration Routes.非肠道给药途径原位凝胶给药系统开发的最新进展
Pharmaceutics. 2020 Sep 10;12(9):859. doi: 10.3390/pharmaceutics12090859.
10
Nanoparticles in Ocular Drug Delivery Systems for Topical Administration: Promises and Challenges.用于局部给药的眼部药物递送系统中的纳米颗粒:前景与挑战。
Curr Pharm Des. 2015;21(36):5212-24. doi: 10.2174/1381612821666150923095155.

引用本文的文献

1
Brinzolamide encapsulated β-cyclodextrin-chondroitin sulfate nanocomplexes anchored chitosan/polycaprolactone nanofibers as an ocular insert for glaucoma treatment.布林佐胺包封的β-环糊精-硫酸软骨素纳米复合物锚定在壳聚糖/聚己内酯纳米纤维上作为用于青光眼治疗的眼用插入物。
Mater Today Bio. 2025 Aug 11;34:102179. doi: 10.1016/j.mtbio.2025.102179. eCollection 2025 Oct.
2
Mathematical Models of Topically and Intravitreally Applied Ranibizumab.玻璃体内及局部应用雷珠单抗的数学模型
Invest Ophthalmol Vis Sci. 2025 Aug 1;66(11):45. doi: 10.1167/iovs.66.11.45.
3
Nanomedicine-Based Ophthalmic Drug Delivery Systems for the Treatment of Ocular Diseases.
用于治疗眼部疾病的基于纳米医学的眼科药物递送系统
Int J Nanomedicine. 2025 Jul 21;20:9221-9249. doi: 10.2147/IJN.S532074. eCollection 2025.
4
Wearing bacteriophages individually with an adhesive drug-loadable nanohelmet for treating ocular infections.佩戴带有可装载药物的粘性纳米头盔的噬菌体以治疗眼部感染。
Sci Adv. 2025 Jul 11;11(28):eadx4183. doi: 10.1126/sciadv.adx4183.
5
Mucoadhesive nanofibers for ocular drug delivery: mechanisms, design strategies, and applications.用于眼部药物递送的黏膜黏附性纳米纤维:作用机制、设计策略及应用
Drug Deliv Transl Res. 2025 Jun 25. doi: 10.1007/s13346-025-01894-w.
6
Indomethacin-incorporated microemulsion-laden contact lenses for improved ocular drug delivery and therapeutic efficacy.载有吲哚美辛微乳的隐形眼镜用于改善眼部药物递送和治疗效果。
RSC Adv. 2025 May 14;15(20):16110-16124. doi: 10.1039/d5ra01046b. eCollection 2025 May 12.
7
Optimization and preparation of in-situ mucoadhesive gel of azithromycin hydroxypropyl-β-cyclodextrin inclusion complex against upper respiratory tract infections.阿奇霉素羟丙基-β-环糊精包合物原位黏膜黏附凝胶的优化制备及其对上呼吸道感染的作用
BMC Pharmacol Toxicol. 2025 Apr 29;26(1):93. doi: 10.1186/s40360-025-00936-w.
8
Nano-based drug delivery systems for the treatment of non-infectious uveitis.用于治疗非感染性葡萄膜炎的纳米药物递送系统。
Adv Ophthalmol Pract Res. 2024 Nov 12;5(2):124-134. doi: 10.1016/j.aopr.2024.11.003. eCollection 2025 May-Jun.
9
External stimuli-responsive drug delivery to the posterior segment of the eye.外部刺激响应性药物递送至眼后段
Drug Deliv. 2025 Dec;32(1):2476140. doi: 10.1080/10717544.2025.2476140. Epub 2025 Mar 24.
10
Long-lasting comfort ocular surface drug delivery by in situ formation of an adhesive lubricative Janus nanocoating.通过原位形成粘性润滑性 Janus 纳米涂层实现长效舒适的眼表药物递送
Sci Adv. 2025 Mar 7;11(10):eads0282. doi: 10.1126/sciadv.ads0282.